BACKGROUND: Natural killer cells have been demonstrated to exert remarkable graft-versus-leukemia effects after haploidentical transplantation. Acquisition of both, inhibiting and activating, receptors on developing natural killer cells is an important step in their functional maturation. Here, we report on the reconstitution of natural killer receptors after haploidentical transplantation of T-and B-cell (CD3/CD19) depleted grafts with co-transfusion of natural killer cells in children and its influence on natural killer cell activity and clinical outcome. DESIGN AND METHODS: We analyzed reconstitution patterns of natural killer receptors at different time intervals after haploidentical transplantation by multi-color flow cytometry. Natural killer cell activity and antibody-dependent cellular cytotoxicity was tested against cell lines and leukemic blasts in vitro. Survival was analyzed using Kaplan-Meier estimates. RESULTS: Recovery of CD56(+)/CD16(+) cells was fast with high cytolytic activity against K562 and strong antibody-dependent cellular cytotoxicity activity against neuroblastoma and leukemic blasts as early as day 14 posttransplant. KIR reconstitution showed a predominance of KIR negative natural killer cells early after transplantation and an early reconstitution of CD158b compared to CD158a and CD158e. These differences were independent of presence or absence of the corresponding KIR ligands in donors or recipients. This reconstitution pattern was associated with a higher relapse probability of patients homozygous for HLA-C1-alleles compared to patients homozygous or even heterozygous for HLA-C2-alleles. CONCLUSIONS: Our results indicate a fast recovery of functional and alloreactive natural killer cells with a constant KIR pattern after haploidentical transplantation with T- and B-cell depleted grafts. Moreover, these natural killer cells can mediate antibody-dependent cellular cytotoxicity and therefore may allow for an early use of antibodies against residual malignant cells.
BACKGROUND: Natural killer cells have been demonstrated to exert remarkable graft-versus-leukemia effects after haploidentical transplantation. Acquisition of both, inhibiting and activating, receptors on developing natural killer cells is an important step in their functional maturation. Here, we report on the reconstitution of natural killer receptors after haploidentical transplantation of T-and B-cell (CD3/CD19) depleted grafts with co-transfusion of natural killer cells in children and its influence on natural killer cell activity and clinical outcome. DESIGN AND METHODS: We analyzed reconstitution patterns of natural killer receptors at different time intervals after haploidentical transplantation by multi-color flow cytometry. Natural killer cell activity and antibody-dependent cellular cytotoxicity was tested against cell lines and leukemic blasts in vitro. Survival was analyzed using Kaplan-Meier estimates. RESULTS: Recovery of CD56(+)/CD16(+) cells was fast with high cytolytic activity against K562 and strong antibody-dependent cellular cytotoxicity activity against neuroblastoma and leukemic blasts as early as day 14 posttransplant. KIR reconstitution showed a predominance of KIR negative natural killer cells early after transplantation and an early reconstitution of CD158b compared to CD158a and CD158e. These differences were independent of presence or absence of the corresponding KIR ligands in donors or recipients. This reconstitution pattern was associated with a higher relapse probability of patients homozygous for HLA-C1-alleles compared to patients homozygous or even heterozygous for HLA-C2-alleles. CONCLUSIONS: Our results indicate a fast recovery of functional and alloreactive natural killer cells with a constant KIR pattern after haploidentical transplantation with T- and B-cell depleted grafts. Moreover, these natural killer cells can mediate antibody-dependent cellular cytotoxicity and therefore may allow for an early use of antibodies against residual malignant cells.
Authors: Sungjin Kim; Jennifer Poursine-Laurent; Steven M Truscott; Lonnie Lybarger; Yun-Jeong Song; Liping Yang; Anthony R French; John B Sunwoo; Suzanne Lemieux; Ted H Hansen; Wayne M Yokoyama Journal: Nature Date: 2005-08-04 Impact factor: 49.962
Authors: M Pfeiffer; S Stanojevic; T Feuchtinger; J Greil; R Handgretinger; K Barbin; G Jung; D Martin; D Niethammer; P Lang Journal: Bone Marrow Transplant Date: 2005-07 Impact factor: 5.483
Authors: M C Mingari; C Vitale; C Cantoni; R Bellomo; M Ponte; F Schiavetti; S Bertone; A Moretta; L Moretta Journal: Eur J Immunol Date: 1997-06 Impact factor: 5.532
Authors: G Carayol; C Robin; J H Bourhis; A Bennaceur-Griscelli; S Chouaib; L Coulombel; A Caignard Journal: Eur J Immunol Date: 1998-06 Impact factor: 5.532
Authors: Peter Parham; Paul J Norman; Laurent Abi-Rached; Lisbeth A Guethlein Journal: Philos Trans R Soc Lond B Biol Sci Date: 2012-03-19 Impact factor: 6.237
Authors: Liron Frishman-Levy; Avishai Shemesh; Allan Bar-Sinai; Chao Ma; Zhenya Ni; Shahar Frenkel; Vera Muench; Hilke Bruckmueller; Christian Vokuhl; Klaus-Michael Debatin; Cornelia Eckert; Martin Stanulla; Martin Schrappe; Kerry S Campbell; Ron Loewenthal; Denis M Schewe; Jacob Hochman; Lueder H Meyer; Dan Kaufman; Gunnar Cario; Angel Porgador; Shai Izraeli Journal: Blood Date: 2015-04-20 Impact factor: 22.113
Authors: Lena Oevermann; Sebastian U Michaelis; Markus Mezger; Peter Lang; Jacek Toporski; Alice Bertaina; Marco Zecca; Lorenzo Moretta; Franco Locatelli; Rupert Handgretinger Journal: Blood Date: 2014-08-12 Impact factor: 22.113
Authors: A Kruchen; T Stahl; F Gieseke; T M C Binder; Z Özcan; R Meisel; H Kreyenberg; P Bader; B Gruhn; J Greil; M Pfeiffer; M Döring; R Handgretinger; B Fehse; I Müller Journal: Bone Marrow Transplant Date: 2015-06-22 Impact factor: 5.483
Authors: Monzr M Al Malki; Mary Horowitz; Rupert Handgretinger; Wing Leung; Denis-Claude Roy; Xiao-Jun Huang; Ephraim Fuchs; Franco Locatelli; Didier Blaise; Shin Mineishi; Massimo Martelli; Jeffrey Miller; Carl June; Hui-Sheng Ai; Leo Luznik; Domenico Mavilio; Enrico Lugli; Marcel R M van den Brink; Richard E Champlin; Stefan O Ciurea Journal: Biol Blood Marrow Transplant Date: 2016-01-13 Impact factor: 5.742
Authors: Matthias Manuel Pfeiffer; Helen Burow; Sabine Schleicher; Rupert Handgretinger; Peter Lang Journal: Front Oncol Date: 2013-04-29 Impact factor: 6.244